A nested case-control study was Performed to investigate the role of hepatitis C virus (HCV) infection in the aetiology of primary liver cancer (PLC), and the interaction between HCV and HBV infection. Subjects were c...A nested case-control study was Performed to investigate the role of hepatitis C virus (HCV) infection in the aetiology of primary liver cancer (PLC), and the interaction between HCV and HBV infection. Subjects were chosen from members of a cohort study held in past years. They were all male, more than 20 years of age, with serum specimens drawn and stored at -20℃. Every death of PLC, occurred since then, as a 'case' (78 in total), was compared with no more than 4 matched controls chosen from the cohort members who were still alive and free of PLC. ELISA technique was used to test for anti-HCV in stored serum samples of cases and controls. The serum HBsAg status were directly quoted from original cohort records. Result showed that anti-HCV prevalence rates were 33.3% (26/78) of the cases and 15.3% (40/262) of their matched controls. The PLC risk of HCV infected members were about 3 times that risk of the other. About 1 quarter of the PLC deaths in studied Population could be attributed to having been infected by HCV. As 2 of the main PLC risk factors. HCV and HBV infection didn't obviously confound each other. The distribution of HCV in the population didn't influence that of HBV, and vice versa.展开更多
文摘A nested case-control study was Performed to investigate the role of hepatitis C virus (HCV) infection in the aetiology of primary liver cancer (PLC), and the interaction between HCV and HBV infection. Subjects were chosen from members of a cohort study held in past years. They were all male, more than 20 years of age, with serum specimens drawn and stored at -20℃. Every death of PLC, occurred since then, as a 'case' (78 in total), was compared with no more than 4 matched controls chosen from the cohort members who were still alive and free of PLC. ELISA technique was used to test for anti-HCV in stored serum samples of cases and controls. The serum HBsAg status were directly quoted from original cohort records. Result showed that anti-HCV prevalence rates were 33.3% (26/78) of the cases and 15.3% (40/262) of their matched controls. The PLC risk of HCV infected members were about 3 times that risk of the other. About 1 quarter of the PLC deaths in studied Population could be attributed to having been infected by HCV. As 2 of the main PLC risk factors. HCV and HBV infection didn't obviously confound each other. The distribution of HCV in the population didn't influence that of HBV, and vice versa.